Research Articles | Page 37 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey Jun 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Nov 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience Sep 2020 Leukemia & Lymphoma Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria Dec 2019 Leukemia & Lymphoma Aplastic Anemia
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Nov 2024 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery? Jun 2023 Leukemia & Lymphoma Aplastic Anemia
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes May 2019 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes May 2019 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Mar 2025 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)